Cyclo(prolylglycyl)

Summary

Cyclo(prolylglycyl) (also called cyclo(L‑Pro‑Gly)₃) is a synthetic cyclic hexapeptide composed of three repeats of the Pro‑Gly dipeptide, forming a diketopiperazine ring. Research to date has focused on its solid‑state characteristics, including crystal packing and its ability to bind calcium ions. The compound is classified as a research‑only cyclic dipeptide and has no approved therapeutic use.

Mechanism of Action

In the solid state, cyclo(L‑Pro‑Gly)₃ serves as a chelating ligand, using the carbonyl oxygens of its glycyl residues to coordinate metal cations. Crystallographic analysis revealed a 2:1 complex with Ca²⁺ where the calcium ion is octahedrally surrounded by six carbonyl oxygens, one from each of two peptide molecules, creating a sandwich‑like arrangement further stabilized by N‑H···O hydrogen bonds. This interaction is a physicochemical binding event rather than a biological mechanism.

What the Research Shows

Two peer‑reviewed papers from 1986 constitute the published record for cyclo(L‑Pro‑Gly)₃. The first described its crystal and molecular structure, noting an asymmetric backbone with five trans and one cis peptide bond, dimer formation via hydrogen bonds, and a trigonal lattice (space group P3₂12). The second paper reported a calcium‑binding complex in which two peptide molecules sandwich a Ca²⁺ ion; the ion is octahedrally coordinated by six carbonyl oxygens at an average distance of 2.26 Å, with additional N‑H···O hydrogen bonds stabilizing the assembly. Both studies employed X‑ray crystallography and did not investigate pharmacology, toxicity, or in‑vivo effects.

Reported Benefits

The documented benefit of cyclo(L‑Pro‑Gly)₃ lies in its utility as a model system for exploring peptide conformation, crystal packing, and metal‑ion coordination. Its defined calcium‑binding geometry may be valuable in structural chemistry or as a scaffold for designing metal‑binding peptides. No therapeutic or functional advantages have been demonstrated in biological contexts.

Limitations of the Evidence

Evidence for cyclo(L‑Pro‑Gly)₃ is limited to crystallographic analyses; there are no data on biological activity, pharmacokinetics, or clinical efficacy. The compound’s behavior in solution, stability under physiological conditions, and potential toxicity remain uncharacterized. Consequently, any extrapolation to therapeutic use is speculative, and the lack of in‑vivo studies represents a major knowledge gap.

Safety Considerations

No safety or toxicology information is provided in the literature. As a synthetic cyclic dipeptide, it may be biologically inert, but without experimental data the risk profile is unknown. Researchers should treat the compound as a chemical reagent, following standard laboratory safety practices and avoiding any assumption of safety for human consumption or medical use.

How It Is Administered

The structured data list intraperitoneal, intravenous, and oral routes as possible administration pathways, reflecting typical routes used in pre‑clinical peptide studies. No specific formulations, dosing regimens, or bioavailability data are reported. Any experimental use would require formulation appropriate to the chosen route (e.g., sterile solution for injection or aqueous suspension for oral delivery).

Routes of Administration

Goals & Uses

• NeuroprotectionNeurologyLow
• Anxiolytic effectNeuropsychiatricLow
• Nootropic / cognitive enhancementCognitiveLow
• AnticonvulsantNeurologicalLow

Contraindications

• Known hypersensitivity to proline or glycine derivativesAllergyHigh

Adverse Effects

• Unknown systemic effectsGeneralUnknown

Drug Interactions

• BenzodiazepinesLow
• GABAergic agentsLow

Population Constraints

• Pregnant or lactating individualsReproductiveRelative
• Pediatric populationsAgeRelative
• ElderlyAgeRelative

Regulatory Status

• European UnionUnapprovedNot EMA-approved; no IMPD or clinical trial registration identified.
• United StatesUnapprovedNot FDA-approved; no IND or clinical trial registration identified.
• United KingdomUnapprovedNot MHRA-approved; research compound only.

Not approved by any major regulatory agency (FDA, EMA, MHRA) for any therapeutic indication. Investigated exclusively in preclinical research settings.

Evidence & Sources

• Crystal and molecular structure of cyclo(L-prolyl-glycyl)3. A cyclic hexapeptide with a cis peptide bond
  Journal ArticleLowKartha G, Aimoto S, Varughese KI1986-01-01T00:00:00.000000Z
• Calcium binding cyclic hexapeptide. Crystal structure of cyclo-(L-prolyl-glycyl)3 calcium complex
  Journal ArticleLowVarughese KI, Aimoto S, Kartha G1986-01-01T00:00:00.000000Z

Frequently Asked Questions